Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Larry G. who wrote (731)	7/27/2000 11:05:58 AM
From: Tim Rogers	Respond to of 792

Attention Business/Medical Editors: Micrologix completes Phase I clinical trial for the prevention of hospital-acquired infections caused by Staphylococcus aureus Trading Symbol MBI (TSE/CDNX) MGIXF (US over the counter) Website www.mbiotech.com VANCOUVER, July 26 /CNW/ - Micrologix Biotech Inc. has completed a US Phase I human clinical trial demonstrating the safety of MBI 853NL, an antibiotic drug being developed for the prevention of hospital-acquired infections caused by Staphylococcus aureus (S. aureus). Micrologix will present the results of this study to the FDA and intends to initiate the next phase of clinical trials in the fourth quarter of this year. The Phase I trial was designed as a randomized, double-blind, placebo- controlled study to assess the safety and tolerability of MBI 853NL applied intranasally to 30 healthy volunteers who are persistent carriers of nasal S. aureus. These subjects were treated for five days with follow-up evaluations performed up to one month following treatment. Although the primary purpose of the study was to assess safety in humans, qualitative nasal cultures were also taken from all subjects three days following completion of therapy (on Day 8). The results from this trial demonstrated that MBI 853NL is safe and well tolerated, with no absorption into the bloodstream. Additionally, all clinical chemistry and hematology test results were normal. At the tested dosage, S. aureus was not completely eliminated as organisms were detected in the nasal cultures taken on Day 8. Micrologix plans to initiate a dose-escalation study in the fourth quarter of this year to further establish safety and quantify the anti-S. aureus activity of MBI 853NL. Background on Nasal Carriage of S. aureus S. aureus is one of the most important causes of the two million hospital- acquired infections that occur each year in the US. This organism is carried in the nasal passages of up to 40% of healthy adults. Clinicians have known for decades that individuals who are nasal carriers of S. aureus are at an increased risk of developing serious staphylococcal infections. Nasal carriers of S. aureus have at least a 3.5-fold increased risk of developing a surgical wound infection, and in certain groups of dialysis patients, the risk of infection is increased by up to 14-fold. Additionally, patients are at risk of being infected by S. aureus carried in the noses of hospital care workers. Studies have shown that eliminating or reducing S. aureus nasal carriage lowers the incidence of hospital-acquired infections and thus should decrease the associated cost of medical care. The current arsenal of antimicrobial drugs for addressing S. aureus carriage is very limited and is diminishing with the onset of resistance to these agents. Due to its unique mode of action, Micrologix's MBI 853NL has superb antibiotic properties, killing both sensitive and methicillin-resistant strains of S. aureus (MRSA) and, as demonstrated in preclinical studies, does not generate resistance itself. These qualities offer significant advantages for the use of MBI 853NL in the infection-control practices of hospitals as well as an adjunctive therapy aimed at reducing the incidence of postoperative and other S. aureus infections. Corporate Profile Micrologix Biotech Inc. is a biopharmaceutical company developing novel drugs to treat severe and life-threatening diseases-particularly those caused by antibiotic-resistant microorganisms. Micrologix's portfolio of antibiotic drug candidates is based on improved analogs of the anti-infective peptides found in the host defense systems of most life forms. These peptides overcome conventional antibiotic resistance and extensive research done by Micrologix and independent researchers indicates that it will be extremely difficult for resistance to develop to them. In addition to MBI 853NL, Micrologix has two other drugs currently in clinical trials in the US 3/4 MBI 226 for the prevention of catheter-related bloodstream infections and MBI 594AN for the treatment of acne. Under FDA fast track designation, the Company plans to initiate a Phase III clinical trial of MBI 226 in September 2000. Micrologix completed a Phase I clinical trial of MBI 594AN in June and anticipates initiating further clinical trials in the fourth quarter of 2000. _______________ Dany Hadary President & CEO

To: Larry G. who wrote (731)	8/31/2000 10:51:10 AM
From: Graham Dellaire	Read Replies (2) \| Respond to of 792

Hello Larry, I'm back in MBI I noticed that the lowest warrant excercise price was 5.50. Quite interesting how that coincides with the stable base MBI stock has established at 5.40-5.60. I think this is a good entry point for anyone on the sidelines... with a possible target of 14.50 by next year (just based on the warrant expectations). Also more money (the 8.6 million raised... see below) means that they can move their peptide drugs further to commercialisation without a pharma and that means when they go to negotiate terms for production/distribution, their cut will be that much greater. Cheers, Graham ----------Aug 30 2000 news item------------- MICROLOGIX BIOTECH INC ("MBI-T;MGIXF-L") - Raises $8.6 Million Dany Hadary, President and CEO of Micrologix Biotech Inc. announced that the Company has received approximately $8.6 million pursuant to the exercise of warrants and after-market support options for the purchase of 3,509,667 common shares. These funds bring the Company's cash position to approximately $63 million and the number of common shares issued and outstanding to 39,311,809. The exercised warrants and after-market support options were issued as part of the special unit financing closed in August 1999. A further 656,416 after-market support options issued in connection with the August 1999 financing and the March 2000 special warrant financing remain outstanding. These after-market support options, which expire at various dates between December 15, 2000 and September 11, 2001, have exercise prices ranging from $5.50 to $14.50 per common share, representing potential proceeds of approximately $6.7 million. Micrologix Biotech Inc. develops novel drugs targeted at severe and life-threatening diseases -- particularly those caused by antibiotic-resistant bacteria. The Company's portfolio of antibiotic drug candidates is based on improved analogs of naturally occurring cationic peptides found in the host defense systems of most life forms. Micrologix currently has three drugs in clinical trials in the US -- MBI 226 for the prevention of catheter-related bloodstream infections, MBI 594AN for the treatment of acne and MBI 853NL for the prevention of hospital-acquired Staphylococcus aureus infections. Under FDA fast track designation, the Company plans to initiate Phase III clinical trials of MBI 226 in September 2000. Micrologix recently completed Phase I clinical trials of MBI 594AN and MBI 853NL and anticipates initiating further clinical trials for these drug candidates during the fourth quarter of 2000.